These innovative agents represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. Trizepatide, on the other hand, targets all three incretin receptors – GLP-1, GIP, and glucagon – leading to a synergistic effect. Bot